May 22 (Reuters) - Eyegate Pharmaceuticals Inc EYEG.O :
* EyeGate receives milestone payment from Valeant Pharmaceuticals (NYSE:VRX) for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients
* EyeGate Pharmaceuticals Inc - granted Valeant exclusive, worldwide commercial and manufacturing rights to co's EyeGate II delivery system and EGP-437 combination product
* EyeGate Pharmaceuticals - co is eligible to receive developmental and sales-based milestones totaling up to about $99.0 million, royalties on valeant's net sales of product Source text for Eikon: ID:nGNXNVAYZa Further company coverage: EYEG.O